^
    11ms
    A Study Evaluating the Safety, Pharmacokinetic and Anti-tumor Activity of RO7428731 in Participants With Glioblastoma (clinicaltrials.gov)
    P1, N=36, Active, not recruiting, Hoffmann-La Roche | N=200 --> 36
    Enrollment change
    |
    EGFRvIII expression
    1year
    Expression of EGFRvIII and its co‑expression with wild‑type EGFR, or putative cancer stem cell biomarkers CD44 or EpCAM are associated with poorer prognosis in patients with hepatocellular carcinoma. (PubMed, Oncol Rep)
    Among agents targeting one or more members of the HER family, the pan‑HER family blocker afatinib was the most effective, inhibiting the proliferation of three out of seven human liver cancer cell lines (LCCLs), while the CDK inhibitor dinacicilib was the most effective agent, inhibiting the proliferation of all human LCCLs tested. Taken together, the present results suggested that EGFRvIII expression and its co‑expression with wtEGFR or CD44 was of prognostic significance. These results also support further investigations of the therapeutic potential of drugs targeting EGFRvIII and other members of the HER family in patients with HCC.
    Journal • Cancer stem
    |
    EGFR (Epidermal growth factor receptor) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • CD44 (CD44 Molecule) • EPCAM (Epithelial cell adhesion molecule)
    |
    EGFR mutation • HER-2 expression • EGFR expression • EGFR wild-type • CD44 expression • EGFRvIII expression
    |
    Gilotrif (afatinib)
    1year
    AB020. Flagellin synergistically enhances anti-tumor effect of EGFRvIII peptide in a glioblastoma-bearing mouse brain tumor model. (PubMed, Chin Clin Oncol)
    FlaB can enhance the anti-tumor effect of PEGFRvIII by increasing CD8+ T cell response in a mouse brain GBM model.
    Preclinical • Journal • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • CD8 (cluster of differentiation 8) • CASP3 (Caspase 3)
    |
    EGFR mutation • EGFRvIII expression
    1year
    A Study Evaluating the Safety, Pharmacokinetic and Anti-tumor Activity of RO7428731 in Participants With Glioblastoma (clinicaltrials.gov)
    P1, N=200, Recruiting, Hoffmann-La Roche | Active, not recruiting --> Recruiting
    Enrollment open
    |
    EGFRvIII expression
    2years
    A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma (clinicaltrials.gov)
    P2, N=0, Withdrawn, Masonic Cancer Center, University of Minnesota | N=36 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR amplification • EGFR expression • EGFRvIII expression • EGFR underexpression
    |
    Modeyso (dordaviprone)
    2years
    D2C7-CAR: A novel, dual-specific chimeric antigen receptor T cell with high specificity for EGFR and EGFRvIII improves survival in EGFR/EGFRvIII glioblastoma and EGFR over-expressing medulloblastoma (SNO 2023)
    D2C7-CAR demonstrates effective preclinical results both in vitro and in vivo. D2C7-CAR is not cytotoxic against human keratinocytes, suggesting it will be well tolerated in clinical trials.
    CAR T-Cell Therapy
    |
    EGFR (Epidermal growth factor receptor) • PRKDC (Protein Kinase, DNA-Activated, Catalytic Subunit)
    |
    EGFR expression • EGFR overexpression • EGFRvIII expression
    2years
    EGFRvIII overexpression and loss of mouse specific CDKN2A in glial cells leads to gliomagenesis in a novel mouse model (SNO 2023)
    Xenograft tumors are reminiscent of the primary tumor, with similar histopathological features and immunohistochemical staining. This novel mouse model can be used to study diffuse glioma with a leptomeningeal component.
    Preclinical
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • FAP (Fibroblast activation protein, alpha) • GFAP (Glial Fibrillary Acidic Protein) • OLIG2 (Oligodendrocyte Transcription Factor 2)
    |
    EGFR overexpression • CDKN2A deletion • EGFRvIII expression • EGFRVIII overexpression
    2years
    Development of a Transgenic Mouse Model Enabling Comparative Analysis of chimeric antigen receptor (CAR)-Expressing Immune Cell Populations for Cancer Immunotherapy (SNO 2023)
    As the extension of the approach, we crossed the EGFRvIII-CAR Tg mice with mice carrying Vav-Cre, which allowed the expression of anti-EGFRvIII CAR in all hematopoietic cells...This transgenic mouse model offers rigorous and reproducible evaluations of CAR-expressing hematopoietic cells. Furthermore, the model provides a platform for developing combination therapies, such as CAR-T plus CAR-NKT or CAR-T plus CAR-NK cells, with potential implications for enhanced cancer treatment strategies.
    Preclinical • IO biomarker • Immune cell
    |
    IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • IL17A (Interleukin 17A) • IL4 (Interleukin 4)
    |
    EGFRvIII expression
    2years
    Ceramide Is Involved in Temozolomide Resistance in Human Glioblastoma U87MG Overexpressing EGFR. (PubMed, Int J Mol Sci)
    This suggests that the enhanced resistance of EGFR+ cells to TMZ is dependent on Cer metabolism. Altogether, our results indicate that EGFRvIII expression confers a TMZ-resistance phenotype to U87MG glioma cells by counteracting Cer increase.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR overexpression • EGFRvIII expression
    |
    temozolomide